A novel mTOR inhibitor is efficacious in a murine model of colitis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 295, Issue 6, 2008, Pages

  Bhonde, Mandar R ^a   Gupte, Ravindra D ^a   Dadarkar, Shruta D ^a   Jadhav, Mahesh G ^a   Tannu, Aditi A ^a   Bhatt, Pooja ^a   Bhatia, Dimple R ^a   Desai, Nikesh K ^a   Deore, Vijaykumar ^a   Yewalkar, Nilambari ^a   Vishwakarma, Ram A ^a   Sharma, Somesh ^a   Kumar, Sanjay ^a   Dagia, Nilesh M ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Colon; Dextran sulfate sodium; IFN ; Inflammation; Mammalian target of rapamycin; T cells

Indexed keywords

GAMMA INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; P2281; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL INFILTRATION; COLITIS; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; WEIGHT REDUCTION; WESTERN BLOTTING;

AMINOPYRIDINES; ANILIDES; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TUMOR NECROSIS FACTOR-ALPHA;

EID: 57349119998     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90537.2008     Document Type: Article

References (59)

1. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, Granger DN, Krieglstein CF. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol 290: G1131-G1137, 2006.
2. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet 35: 323-330, 2003.
3. Assi K, Pillai R, Gomez-Munoz A, Owen D, Salh B. The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis. Immunology 118: 112-121, 2006.
4. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 263: 591-596, 2008.
5. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657, 2007.
6. Bisping G, Lugering N, Lutke-Brintrup S, Pauels HG, Schurmann G, Domschke W, Kucharzik T. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol 123: 15-22, 2001.
7. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin, a potent inhibitor of T cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 83: 600-609, 1994.
8. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 102: 2058-2069, 2007.
9. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 6: 205-214, 2000.
10. Dagia NM, Gadhoum SZ, Knoblauch CA, Spencer JA, Zamiri P, Lin CP, Sackstein R. G-CSF induces E-selectin ligand expression on human myeloid cells. Nat Med 12: 1185-1190, 2006.
11. Dagia NM, Harii N, Meli AE, Sun X, Lewis CJ, Kohn LD, Goetz DJ. Phenyl methimazole inhibits TNF-alpha-induced VCAM-1 expression in an IFN regulatory factor-1-dependent manner and reduces monocytic cell adhesion to endothelial cells. J Immunol 173: 2041-2049, 2004.
12. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114: 385-391, 1998.
13. Dos Santos S, Delattre AI, De Longueville F, Bult H, Raes M. Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kappaB and PI3K/mTOR signaling pathways. Ann NY Acad Sci 1096: 70-77, 2007.
14. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 9: 375-380, 2008.
15. Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, Herfarth H, Schlitt HJ, Geissler EK. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis 21: 747-753, 2006.
16. Fiorucci S, Antonelli E, Distrutti E, Del Soldato P, Flower RJ, Clark MJ, Morelli A, Perretti M, Ignarro LJ. NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci USA 99: 15770-15775, 2002.
17. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 83: 493-498, 2008.
18. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
19. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
20. Hu L, Li ZR, Wang YM, Wu Y, Jiang JD, Boykin DW. Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents. Bioorg Med Chem Lett 17: 1193-1196, 2007.
21. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968, 2006.
22. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, Richardson DR. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 50: 3716-3729, 2007.
23. Kameda H. [Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases]. Nihon Rinsho Meneki Gakkai Kaishi 30: 165-173, 2007.
24. Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 18: 435-440, 2002.
25. Kitajima S, Takuma S, Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 49: 9-15, 2000.
26. Krieglstein CF, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G, Grisham MB, Ross CR, Granger DN. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 194: 1207-1218, 2001.
27. Kristof AS, Marks-Konczalik J, Billings E, Moss J. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J Biol Chem 278: 33637-33644, 2003.
28. Lange S, Delbro DS, Jennische E, Mattsby-Baltzer I. The role of the Lps gene in experimental ulcerative colitis in mice. APMIS 104: 823-833, 1996.
29. Laukoetter MG, Nava P, Lee WY, Severson EA, Capaldo CT, Babbin BA, Williams IR, Koval M, Peatman E, Campbell JA, Dermody TS, Nusrat A, Parkos CA. JAM-A regulates permeability and inflammation in the intestine in vivo. J Exp Med 204: 3067-3076, 2007.
30. Leon LG, Carballo RM, Vega-Hernandez MC, Martin VS, Padron JI, Padron JM. Antiproliferative activity of 2-alkyl-4-halopiperidines and 2-alkyl-4-halo-1,2,5,6-tetrahydropyridines in solid tumor cell lines. Bioorg Med Chem Lett 17: 2681-2684, 2007.
31. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clement-Lacroix P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862-872, 2007.
32. Lohar MV, Mundada R, Bhonde M, Padgaonkar A, Deore V, Yewalkar N, Bhatia D, Rathos M, Joshi K, Vishwakarma RA, Kumar S. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway. Bioorg Med Chem Lett 18: 3603-3606, 2008.
33. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 445: 866-873, 2007.
34. Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, Hamanaka Y, Inoue M, Nishida T, Matsuda H, Sawa Y. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol 148: 348-359, 2007.
35. Mori M, Stokes KY, Vowinkel T, Watanabe N, Elrod JW, Harris NR, Lefer DJ, Hibi T, Granger DN. Colonic blood flow responses in experimental colitis: time course and underlying mechanisms. Am J Physiol Gastrointest Liver Physiol 289: G1024-G1029, 2005.
36. Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66: 4715-4724, 2006.
37. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38: 1722-1734, 1993.
38. Panes J, Granger DN. Leukocyte-endothelial cell interactions: implications for the pathogenesis and treatment of gastrointestinal disease. Dig Dis 12: 232-241, 1994.
39. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319: 627-630, 2008.
40. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195-199, 2006.
41. Quintela JM, Peinador C, Veiga C, Gonzalez L, Botana LM, Alfonso A, Riguera R. Synthesis and antiallergic activity of pyridothienopyrimidines. Bioorg Med Chem 6: 1911-1925, 1998.
42. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18: 2507-2517, 1999.
43. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, Brady HJ, Savill JS, Dransfield I, Haslett C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12: 1056-1064, 2006.
44. Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243: 833-842; discussion 843-834, 2006.
45. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 14: 181-187, 2008.
46. Sakata A, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Toda A, Eyanagi R, Soeda S. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Immunology 122: 54-64, 2007.
47. Sakaue H, Nishizawa A, Ogawa W, Teshigawara K, Mori T, Takashima Y, Noda T, Kasuga M. Requirement for 3-phosphoinositide-dependent kinase-1 (PDK-1) in insulin-induced glucose uptake in immortalized brown adipocytes. J Biol Chem 278: 38870-38874, 2003.
48. Sakhalkar HS, Hanes J, Fu J, Benavides U, Malgor R, Borruso CL, Kohn LD, Kurjiaka DT, Goetz DJ. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J 19: 792-794, 2005.
49. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633, 2004.
50. Scott WJ, Dumas J, Boyer S, Lee W, Chen Y, Phillips B, Verma S, Chen J, Chen Z, Fan J, Raudenbush B, Reman A, Yi L, Zhu Q, Adnane L, investors. Novel cyanopyridine derivatives useful in the treatment of cancer and other disoiders. US patent application 20040235829, November 25, 2004.
51. Sekine C, Sugihara T, Miyake S, Hirai H, Yoshida M, Miyasaka N, Kohsaka H. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 180: 1954-1961, 2008.
52. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, Nakagawa H, Ogura K, Omata M. Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 179: 2681-2685, 2007.
53. Sturm A, de Souza HS, Fiocchi C. Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets 9: 381-387, 2008.
54. Tatsumi K, Yamauchi T, Kiyono K, Kishi K, Yanagihara Y, Imaoka T, Kawaguchi T, Kubo M. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem (Tokyo) 114: 912-918, 1993.
55. Tominaga Y, Tamguney T, Kolesnichenko M, Bilanges B, Stokoe D. Translational deregulation in PDK-1-/- embryonic stem cells. Mol Cell Biol 25: 8465-8475, 2005.
56. Vetuschi A, Latella G, Sferra R, Caprilli R, Gaudio E. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 47: 1447-1457, 2002.
57. Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF, Granger DN. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 49: 556-564, 2004.
58. Weinstein SL, Finn AJ, Dave SH, Meng F, Lowell CA, Sanghera JS, DeFranco AL. Phosphatidylinositol 3-kinase and mTOR mediate lipopolysaccharide-stimulated nitric oxide production in macrophages via interferon-beta. J Leukoc Biol 67: 405-414, 2000.
59. Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 102: 13622-13627, 2005.